跳至主要内容
临床试验/NCT07044791
NCT07044791进行中(未招募)不适用

Metabolic Parameters and Quality of Life in Women on Neo-/Adjuvant Therapy for Breast Cancer: a Randomized Controlled Trial on the Effectiveness of an Intensive Dietary Intervention

Federico II University1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2018年2月2日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
120
试验地点
1
主要终点
Body weight control

研究概览

简要总结

The present trial aims to compare the effectiveness of an "intensive" vs a "standard" nutritional intervention on body weight regulation and some metabolic parameters in women on adjuvant/neoadjuvant therapy for breast cancer.

详细描述

The effectiveness of an "intensive" versus "non-intensive" dietary intervention will be assessed in 120 patients on adjuvant therapy for breast cancer (BC) in a prospective, randomized controlled study for a total of 3 years. The eligibility of participants will be verified according to the inclusion/exclusion criteria at the screening visit; therefore, after a detailed explanation of the study protocol, Informed Consent will be signed. After the recruitment, subjects will be randomized into an "intensive" (ARM A) and "non-intensive" (ARM B) dietary intervention group. After the 6 month treatment period, patients will be followed up for the following 18 months.

ARM A: Visits will be set up monthly in order to assess body weight, waist circumference, diet compliance (etc...) for all period of the BC adjuvant treatment (6 months).

ARM B: Visits will be set up only at the baseline, after 6 months namely at the end.

No drug treatment will be given to patients during the trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •Women ≥18 years old
  • •BMI < 30 kg/m2
  • •Caucasians
  • •Histological diagnosis of invasive breast cancer
  • •Starting an adjuvant systemic treatment for breast cancer
  • •Available past medical history
  • •Informed consent to participate to the study

排除标准

  • •Metastatic disease
  • •BMI >30 kg/m2
  • •Presence of a serious medical condition that could alter food absorption or prognosis
  • •Refusal to provide informed consent to participate in the study

研究组 & 干预措施

ARM A: intensive nutritional intervention

Experimental

ARM A: Visits will be set up monthly in order to assess body weight, waist circumference, diet compliance (etc...) for all period of the BC adjuvant treatment (6 months).

干预措施: Nutritional counseling. No drug treatment will be administered in this study. (Behavioral)

ARM B: standard nutritional intervention

No Intervention

ARM B: Visits will be set up only at the baseline, after 6 months namely at the end

结局指标

主要结局

Body weight control

时间窗: 12 months

To investigate the effects of an intensive nutritional intervention on Body weight control (defined as weight changes ≤+5% of the initial body weight) at 12 months after the beginning of systemic treatment.

Body weight control

时间窗: 12 months

To investigate the effects of an intensive nutritional intervention on Body weight control (defined as weight changes ≤+5% of the initial body weight) at 12 months after the beginning of systemic treatment.

次要结局

  • Change from Baseline in the Mean concentration of urate(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Aspartate Amino Transaminase(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Alanine AminoTransferase(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Gamma-Glutamyl Transferase(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Alkaline Phosphatase(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of erythrocytes Sedimentation Rate(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of C-reactive protein(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Thyroid-stimulating hormone(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Free Triiodothyronine(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Free thyroxine(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of LDL cholesterol(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of triglycerides(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of urea(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of vitamin D(From enrollment to 6,12 and 24 months)
  • Body Mass Index (BMI)(From enrollment to 6, 12 and 24 months)
  • Body composition(From enrollment to 6, 12 and 24 months)
  • Resting energy expenditure (REE)(From enrollment to 6, 12 and 24 months)
  • Quality of life (QoL)(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Fasting glucose(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Serum insulin (mg/dl)(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of C-peptide (ng/ml)(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of glycosylated haemoglobin(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of total cholesterol(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of creatinine(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Free Triiodothyronine(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Aspartate Amino Transaminase(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of erythrocytes Sedimentation Rate(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of LDL cholesterol(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of triglycerides(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of creatinine(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of urate(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Free thyroxine(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of vitamin D(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of total cholesterol(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Alanine AminoTransferase(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Alkaline Phosphatase(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of C-reactive protein(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Thyroid-stimulating hormone(From enrollment to 6,12 and 24 months)
  • Body composition(From enrollment to 6, 12 and 24 months)
  • Body weight(From enrollment to 6, 12 and 24 months)
  • Body Mass Index (BMI)(From enrollment to 6, 12 and 24 months)
  • Resting energy expenditure (REE)(From enrollment to 6, 12 and 24 months)
  • Quality of life (QoL)(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Serum insulin (mg/dl)(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of C-peptide (ng/ml)(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of glycosylated haemoglobin(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of HDL cholesterol(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Fasting glucose(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of urea(From enrollment to 6,12 and 24 months)
  • Change from Baseline in the Mean concentration of Gamma-Glutamyl Transferase(From enrollment to 6,12 and 24 months)

研究者

发起方
Federico II University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Grazia Arpino

Principal Investigator

Federico II University

研究点 (1)

Loading locations...

相似试验